Detalhe da pesquisa
1.
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Cancer Immunol Immunother
; 73(8): 142, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38832989
2.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634928
3.
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Cancer Immunol Immunother
; 72(6): 1365-1379, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633661
4.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
5.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676282
6.
High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?
Curr Treat Options Oncol
; 23(7): 1001-1013, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35501552
7.
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Oncologist
; 26(11): 941-949, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34190375
8.
Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
Int J Mol Sci
; 22(2)2021 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451055
9.
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Oncologist
; 25(9): 745-e1265, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32045050
10.
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
Int J Mol Sci
; 21(14)2020 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32668761
11.
Tyrosine Kinase Receptors in Oncology.
Int J Mol Sci
; 21(22)2020 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33198314
12.
Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.
Oncologist
; 24(7): e597-e599, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30877189
13.
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.
Int J Mol Sci
; 20(19)2019 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597249
14.
Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Int J Mol Sci
; 20(8)2019 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999623
15.
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Oncologist
; 21(6): 701-7, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27107003
17.
Tumor-associated macrophages: "Good cop-bad cop".
Cancer
; 125(11): 1941-1942, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30748000
18.
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Clin Genitourin Cancer
; 22(2): 305-314.e3, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38087702
19.
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Clin Exp Metastasis
; 2024 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38850317
20.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Eur Urol Oncol
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575409